Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M288Revenue $M14.7Net Margin (%)-174.1Altman Z-Score-4.6
Enterprise Value $M209EPS $-0.5Operating Margin %-219.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-175.5Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.8Cash flow > EarningsN
Price/Sales17.85-y EBITDA Growth Rate %-16.2Current Ratio2.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M71.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with THLD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THLDFirst Eagle Investment 2015-03-31 Add$3.33 - $4.61
($3.99)
$ 4.041%Add 2.06%1,405,768
THLDFirst Eagle Investment 2014-12-31 Add$2.7 - $3.56
($3.02)
$ 4.0434%Add 26.17%1,377,448
THLDFirst Eagle Investment 2014-09-30 Add$3.75 - $5.03
($4.2)
$ 4.04-4%Add 36.46%1,091,700
THLDFirst Eagle Investment 2014-03-31 Add0.01%$4.34 - $5.72
($4.92)
$ 4.04-18%Add 250.00%700,000
THLDFirst Eagle Investment 2012-12-31 Buy $3.98 - $6.55
($4.67)
$ 4.04-13%New holding200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THLD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


THLD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JAEGER WILFRED EDirector 2015-02-18Buy25,000$3.755.07view
Davar NipunVice President 2014-10-13Buy3,000$2.9931.77view
YOUNGER WILLIAM H JR10% Owner 2014-10-01Sell242,396$3.774.51view
WHITE JAMES N10% Owner 2014-10-01Sell239,538$3.774.51view
SWEET DAVID E10% Owner 2014-10-01Sell229,154$3.774.51view
Speiser Michael L10% Owner 2014-10-01Sell227,228$3.774.51view
SHEEHAN ANDREW T10% Owner 2014-10-01Sell230,352$3.774.51view
Pullara Samuel J III10% Owner 2014-10-01Sell226,657$3.774.51view
GAITHER JAMES C10% Owner 2014-10-01Sell231,287$3.774.51view
Dyckerhoff Stefan A10% Owner 2014-10-01Sell226,657$3.774.51view

Press Releases about THLD :

Quarterly/Annual Reports about THLD:

News about THLD:

Articles On GuruFocus.com
Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL May 12 2015 
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus De Dec 06 2014 
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in Dece Nov 25 2014 
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevaciz Nov 17 2014 
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previo Nov 11 2014 
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conferenc Nov 10 2014 
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented Nov 06 2014 
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at Nov 03 2014 
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in th Nov 03 2014 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 

More From Other Websites
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 10 2015
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 01 2015
Threshold Pharmaceuticals Presents Encouraging Preliminary Phase 2 Data in Multiple Myeloma at ASCO May 31 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies 2015 Healthcare... May 27 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies 2015 Healthcare... May 27 2015
Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be... May 13 2015
Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be... May 13 2015
5 New Biotech Developments Worth Watching May 13 2015
Threshold Pharmaceuticals (THLD) Stock Soars on FDA Fast Track Designation May 12 2015
Merck KGaA, Threshold win fast track for pancreatic cancer drug May 12 2015
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track... May 12 2015
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track... May 12 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 UBS Global Healthcare... May 11 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 UBS Global Healthcare... May 11 2015
Are These in Your Portfolio? 4 Trending Companies (GALE, AEZS, PPCH, THLD) May 06 2015
10-Q for Threshold Pharmaceuticals, Inc. May 03 2015
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 30 2015
Threshold Pharmaceuticals Reports First Quarter 2015 Financial and Operational Results Apr 30 2015
Threshold Pharmaceuticals Reports First Quarter 2015 Financial and Operational Results Apr 30 2015
THLD: Phase II Clinical Trials of TH-4000 Will Be Initiated in 2015 Apr 27 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK